Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
07 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/07/2976768/0/en/Clearside-Biomedical-Partner-Arctic-Vision-Executes-Commercial-Collaboration-Agreement-with-Santen-Pharmaceutical-Co-Ltd-for-ARVN001-Suprachoroidal-Space-Injection-Therapy-for-the-.html
28 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/28/2906122/0/en/NurExone-s-ExoPTEN-Being-Studied-as-Glaucoma-Treatment-for-US-3-4-Billion-Market.html
18 Jul 2023
// BUSINESSWIRE
06 Oct 2022
// BUSINESSWIRE
28 Sep 2022
// Kevin Dunleavy FIERCEPHARMA
https://www.fiercepharma.com/pharma/santen-scores-another-fda-eye-drops-nod-time-glaucoma-and-ocular-hypertension
26 Sep 2022
// BUSINESSWIRE
Details:
Catiolanze® is a preservative-free latanoprost 50μg/mL eye drop cationic emulsion. The active substance latanoprost, a prostaglandin F2α analogue, is a selective proteinoid FP receptor agonist which reduces the IOP by increasing the outflow of aqueous humor.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Brand Name: Catiolanze
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Santen Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost ...
Details : Catiolanze® is a preservative-free latanoprost 50μg/mL eye drop cationic emulsion. The active substance latanoprost, a prostaglandin F2α analogue, is a selective proteinoid FP receptor agonist which reduces the IOP by increasing the outflow of aqueous...
Brand Name : Catiolanze
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2023
Details:
Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationorm PLUS.
Lead Product(s): Fluorometholone Acetate
Therapeutic Area: Ophthalmology Brand Name: Flarex
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 24, 2023
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and...
Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...
Brand Name : Flarex
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 24, 2023
Details:
Under the agreement, Visiox gain rights to product manufacturing, commercialization, and sales of Omlonti (omidenepag isopropyl), an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Lead Product(s): Omidenepag Isopropyl
Therapeutic Area: Ophthalmology Brand Name: Omlonti
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Visiox Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 18, 2023
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Visiox Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Visiox gain rights to product manufacturing, commercialization, and sales of Omlonti (omidenepag isopropyl), an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Brand Name : Omlonti
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 18, 2023
Details:
Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationorm PLUS.
Lead Product(s): Fluorometholone Acetate
Therapeutic Area: Ophthalmology Brand Name: Flarex
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 17, 2023
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...
Brand Name : Flarex
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 17, 2023
Details:
STN1011101, a preservative-free combination eye drop of tafluprost 0.0015% and timolol 0.5%. It is being developed for lowering intraocular pressure of patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Tafluprost,Timolol Maleate
Therapeutic Area: Ophthalmology Brand Name: STN1011101
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Lead Product(s) : Tafluprost,Timolol Maleate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : STN1011101, a preservative-free combination eye drop of tafluprost 0.0015% and timolol 0.5%. It is being developed for lowering intraocular pressure of patients with open-angle glaucoma or ocular hypertension.
Brand Name : STN1011101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 08, 2023
Details:
Cationorm® Plus (glycerol) is a sterile, preservative-free, artificial tear containing the novel Novasorb® technology. As the only artificial tear that uses positive cationic emulsion to hold hydration in place, it protects, hydrates and lubricates the eye.
Lead Product(s): Glycerine,Tyloxapol API,Detalan
Therapeutic Area: Ophthalmology Brand Name: Cationorm Plus
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Lead Product(s) : Glycerine,Tyloxapol API,Detalan
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Santen Announces Health Canada Approval for Cationorm® Plus to Relieve the Symptoms of Dry Eye an...
Details : Cationorm® Plus (glycerol) is a sterile, preservative-free, artificial tear containing the novel Novasorb® technology. As the only artificial tear that uses positive cationic emulsion to hold hydration in place, it protects, hydrates and lubricates the...
Brand Name : Cationorm Plus
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2022
Details:
OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Omidenepag Isopropyl
Therapeutic Area: Ophthalmology Brand Name: Omlonti
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: UBE Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : UBE Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.00...
Details : OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension...
Brand Name : Omlonti
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2022
Details:
Verkazia (cyclosporine) is a prescription-only, uniquely formulated cationic nanoemulsion that provides improved ocular bioavailability of cyclosporine, which has been shown to be effective in the management of VKC.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Brand Name: Verkazia
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of V...
Details : Verkazia (cyclosporine) is a prescription-only, uniquely formulated cationic nanoemulsion that provides improved ocular bioavailability of cyclosporine, which has been shown to be effective in the management of VKC.
Brand Name : Verkazia
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 02, 2022
Details:
Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rhopressa and Rocklatan.
Lead Product(s): Netarsudil
Therapeutic Area: Ophthalmology Brand Name: Rhopressa
Study Phase: ApprovedProduct Type: Small molecule
Recipient: Alcon Inc
Deal Size: $168.0 million Upfront Cash: $88.0 million
Deal Type: Expanded Collaboration December 07, 2021
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : Alcon Inc
Deal Size : $168.0 million
Deal Type : Expanded Collaboration
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe ...
Details : Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rho...
Brand Name : Rhopressa
Molecule Type : Small molecule
Upfront Cash : $88.0 million
December 07, 2021
Details:
The agreement aims for SYD-101, Sydnexis’ investigational proprietary low dose atropine sulfate formulation, for Europe, Middle East and Africa (EMEA), is currently undergoing a phase III clinical trial, the STAAR study, in Europe and the US to help control myopia progression.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Brand Name: SYD-101
Study Phase: Phase IIIProduct Type: Small molecule
Recipient: Sydnexis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 10, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Sydnexis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for SYD-101, Sydnexis’ investigational proprietary low dose atropine sulfate formulation, for Europe, Middle East and Africa (EMEA), is currently undergoing a phase III clinical trial, the STAAR study, in Europe and the US to help co...
Brand Name : SYD-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2021
ABOUT THIS PAGE
Santen Pharmaceutical is a supplier offers 7 products (APIs, Excipients or Intermediates).
Find a price of Sennosides bulk with JDMF offered by Santen Pharmaceutical
Find a price of Bucillamine bulk offered by Santen Pharmaceutical
Find a price of Rivoglitazone Hydrochloride bulk offered by Santen Pharmaceutical
Find a price of Tiopronin bulk offered by Santen Pharmaceutical
Find a price of Tropicamide bulk offered by Santen Pharmaceutical
Find a price of MANUFACTURING PLANT AT NOTO, JAPAN bulk offered by Santen Pharmaceutical
Find a price of FACILITIES AND PROCEDURES IN TAMPERE, FINLAND bulk offered by Santen Pharmaceutical
LOOKING FOR A SUPPLIER?